MoneycontrolMoneycontrol

Neutral Torrent Pharma; target of Rs 4970: Motilal Oswal

1분 미만 읽기

Motilal Oswal's research report on Torrent Pharma

Torrent Pharma (TRP) delivered slightly better-than-expected revenue/EBITDA (+3%/5%) for the quarter. Earnings were largely in line with estimates due to higher-than-expected tax rate for the quarter. TRP outperformed domestic formulation industry (IPM) growth by a wide margin, led by market share gains in chronic therapies, robust scale-up of Curatio portfolio, and healthy market share in the Semaglutide product. Notably, TRP outpaced the Brazilian branded generics market, led by new launches, volume growth, pricing, and inventory normalization.

Outlook

We value TRP at 52x 12-month forward earnings to arrive at a TP of INR4,970. We remain constructive on TRP's domestic growth prospects, expanding Semaglutide opportunity and potential earnings benefits from JB Pharma integration.

면책사항

기사 전문을 읽어보세요
TradingView에서 Moneycontrol 비롯한 모든 뉴스 소스의 기사에 무제한으로 액세스하세요.